(1-(4-(Naphthalen-2-yl)pyrimidin-2-yl)piperidin-4-yl)methanamine: A wingless β-catenin agonist that increases bone formation rate
A high-throughput screening campaign to discover small molecule leads for the treatment of bone disorders concluded with the discovery of a compound with a 2-aminopyrimidine template that targeted the Wnt β-catenin cellular messaging system. Hit-tolead in
Pelletier, Jeffrey C.,Lundquist IV, Joseph T.,Gilbert, Adam M.,Alon, Nipa,Bex, Frederick J.,Bhat, Bheem M.,Bursavich, Mattew G.,Coleburn, Valerie E.,Felix, Luciana A.,Green, Daniel M.,Green, Paula,Hauze, Diane B.,Kharode, Yogendra P.,Lam, Ho-Sun,Lockhead, Susan R.,Magolda, Ronald L.,Matteo, Jeanne J.,Mehlmann, John F.,Milligan, Colleen,Murrills, Richard J.,Pirrello, Jennifer,Selim, Sally,Sharp, Michael C.,Unwalla, Ray J.,Vera, Matthew D.,Wrobel, Jay E.,Yaworsky, Paul,Bodine, Peter V. N.
supporting information; experimental part
p. 6962 - 6965
(2010/08/03)
NAPHTHYLPYRIMIDINE, NAPHTHYLPYRAZINE AND NAPHTHYLPYRIDAZINE ANALOGS AND THEIR USE AS AGONISTS OF THE WNT-BETA-CATENIN CELLULAR MESSAGING SYSTEM
The present invention relates to naphthylpyrimidine analogs, methods of making naphthylpyrimidine analogs, compositions comprising a naphthylpyrimidine analog, and methods for treating canonical Wnt-β-catenin cellular messaging system-related disorders co
-
Page/Page column 27
(2009/04/24)
More Articles about upstream products of 1123231-07-1